The Pro Medicus (ASX:PME) share price zoomed 25% higher in January

The Pro Medicus Limited (ASX:PME) share price was a very strong performer in January. Here's why it zoomed 25% higher during the month…

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price was an impressive performer in January.

It was among the best performers on the S&P/ASX 200 Index (ASX: XJO) with a 25.4% monthly gain.

This means the Pro Medicus share price is now up a massive 71% over the last 12 months.

Why did the Pro Medicus share price rocket higher in January?

The catalyst for the strong performance by the Pro Medicus share price in January was the announcement of another major contract win.

This was the sixth such an announcement in the space of eight months and follows previously announced deals with Ludwig-Maximilians University, MedStar Health, Northwestern Memorial Healthcare, and NYU Langone Health. It was also the fifth win in just six months.

The latest contract is with Salt Lake City-based Intermountain Healthcare and is the biggest of them all. Management revealed that it is worth a sizeable $40 million over a seven-year period.

According to the release, Intermountain Healthcare is the largest health system in the State of Utah. It also provides medical services in the states of Idaho and Nevada.

The contract, which is based on a transactional licensing model, will see the company's Visage 7 Viewer and Visage 7 Open Archive products implemented across all of Intermountain's radiology and subspecialty imaging departments.

The implementation will be fully deployed on Google Cloud Platform (GCP), leveraging Visage's native, cloud-engineered enterprise imaging technology.

Pro Medicus' CEO, Dr Sam Hupert, commented: "This is a very important deal for us, not only because of its size and scope, it will provide us with a material footprint in Intermountain West, previously an untapped region for us."

"Prestigious deals"

In a separate Q&A release, Dr Hupert spoke in more detail about its recent contract wins.

Commenting on what the deal says about its technology, Dr Hupert said: "Firstly, these were arguably five of the largest, most prestigious deals in the market not to mention that these sorts of deals don't come around often, so they were incredibly competitive. The fact that we won five out of five we feel validates our belief that we have a unique, highly differentiated offering."

"Secondly, I think people are hearing about the ROI we deliver, both financially and clinically. This combined with our ability to rapidly and seamlessly implement is creating a strong network effect that has been instrumental in our spate of recent wins," he added.

Looking ahead, the Chief Executive remains positive on its outlook thanks to its strong pipeline of opportunities.

He explained: "In terms of the pipeline, there have been a number of new opportunities, particularly over the past 6-8 months that supplement those already in the pipeline that are progressing through the cycle. So, whilst we have been very successful in converting end-stage opportunities such as Intermountain and the other deals we have announced over the past 6 months, our pipeline remains strong with a range of opportunities across various stages of the cycle and across multiple segments of the market."

This may bode well for the Pro Medicus share price over the next 12 months.

Should you invest $1,000 in Pro Medicus Limited right now?

Before you buy Pro Medicus Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pro Medicus Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a spectacular end to the trading week for the ASX today.

Read more »

Three people jumping cheerfully in clear sunny weather.
Share Gainers

These 3 ASX 200 stocks are shooting the lights out this week. Own any?

These ASX 200 shares have soared 11% to almost 23% this week. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Share Gainers

Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher

These shares are ending the week on a positive note. But why?

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a momentous day for ASX shares, with the index hitting another record...

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why ASX, Domain, Ora Banda, and Temple & Webster's shares are storming higher today

These shares are catching the eye with strong gains on Thursday. Let's see what is happening.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

2 ASX 300 shares rocketing 6% today

Investors love what these two stocks just reported.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a wonderful Wednesday session for investors today...

Read more »